

Ministry of Health

Ministère de la Santé

Office of Chief Medical Officer of Health, Public Health Bureau du médecin hygiéniste en chef, santé publique

Box 12

Boîte à lettres 12 Toronto ON M7A 1N3

Toronto ON M7A 1N3 **Tel.:** 416 212-3831

Fax: 416 325-8412

Tél.: 416 212-3831 **Téléc.**: 416 325-8412

May 3, 2022

SECTION 77.6 HEALTH PROTECTION AND PROMOTION ACT CHIEF MEDICAL OFFICER OF HEALTH ORDER order to Public Hospitals to provide information relating to severe acute hepat

(Order to Public Hospitals to provide information relating to severe acute hepatitis of unknown origin among children)

ONTARIO MINISTRY OF HEALTH

ORDER OF THE CHIEF MEDICAL OFFICER OF HEALTH UNDER SECTION 77.6 OF THE HEALTH PROTECTION AND PROMOTION ACT, R.S.O. 1990, c. H.2 (The Act)

WHEREAS under section 77.6 of the Act, the Chief Medical Officer of Health, where he is of the opinion that there exists an immediate and serious risk to the health of persons anywhere in Ontario, may issue an order directing any health information custodian, as defined in the *Personal Health Information Protection Act*, 2004 to provide to the Chief Medical Officer of Health or his or her delegate with any information provided in the order;

AND WHEREAS, under section 77.6(2), the Chief Medical Officer of Health is of the opinion, based on reasonable and probable grounds, that the information is necessary to investigate, eliminate or reduce the immediate and serious risk to the health of persons in Ontario presented by severe acute hepatitis of unknown origin among children;

AND WHEREAS, under section 77.6(3), the information requested in this order is to be used or disclosed only to investigate, eliminate or reduce the risk and for no other purpose;

AND WHEREAS, under section 77.6(1), the Chief Medical Officer of Health may require health information custodians named in the order to disclose information, including personal health information, to a delegate;

AND HAVING REGARD TO severe acute hepatitis of unknown origin in children observed internationally as follows: Since October 2021, there have been, as of the date of this Order, at least 169 cases of acute hepatitis of unknown origin reported among children aged one month up to 16 years of age in countries throughout Europe (UK, Ireland, Denmark, the Netherlands, Spain, Italy, Norway, France, Romania, and Belgium), Israel, and the United States.

These cases are negative for hepatitis viruses A, B, C, D and E and have aspartate transaminase (AST) or alanine transaminase (ALT) levels over 500 U/L. The aetiology is considered unknown and active investigation continues; however, SARS-CoV-2 and adenovirus have been identified in some cases.

AND HAVING REGARD TO some cases having required transfers to specialist children's liver units, some having required liver transplantation, and there being at least one death reported as a result of infection.

THE CHIEF MEDICAL OFFICER OF HEALTH THEREFORE ORDERS pursuant to the provisions of section 77.6 of the Act that:

- 1. Every person or entity who operates a hospital within the meaning of the *Public Hospitals Act* ("Public Hospital"), any institution, building or other premises or place that is established for the purposes of the treatment of patients and that is approved under the *Public Hospitals Act* as a Public Hospital, must provide to the Chief Medical Officer of Health's delegate, the Ontario Agency for Health Protection and Promotion ("Public Health Ontario"), the information as outlined in Appendix B ("Case Report Form") respecting any cases of severe acute hepatitis of unknown origin among patients who are children ("Patients") and who meet the probable or epi-linked case definition in Appendix A (the "Information"). The Public Hospital must make best efforts to obtain the information from the parent or guardian (or child, where applicable) noted in sections 7 to 11 of the Case Report Form (Appendix B).
- 2. Every Public Hospital must disclose the Information to Public Health Ontario within one (1) business day after the Public Hospital learns that it has a Patient who meets the probable or epi-linked case definition in Appendix A.
- 3. Every Public Hospital must disclose the Information to Public Health Ontario. If a Public Hospital has a Patient that meets the probable or epi-linked case definition in Appendix A, the Public Hospital must contact Public Health Ontario at 647- 260-7419 and provide the name and contact information for a representative of the Public Hospital that can be

contacted by Public Health Ontario to report the information in the Case Report Form. Outside of business hours, a Public Hospital representative can call the above telephone number and leave a message, absent of personal health information.

This Order takes effect immediately and shall remain in force until revoked.

Dated at Toronto this 3rd day of May, 2022.

Dr. Kieran M. Moore

Chief Medical Officer of Health

To And

APPENDIX A

CASE DEFINITIONS for severe acute hepatitis of unknown origin in children.

Confirmed case

N/A at present.

Probable case

A person presenting with an acute hepatitis (non hep A-E*) with serum transaminase
 >500 IU/L (AST or ALT), who has been 16 years of age or younger in the period between 1 October 2021 and the present.

Epi-linked

• A person presenting with an acute hepatitis (non hep A-E*) of any age who has been a close contact of a probable case at any point during the period between 1 October 2021 and the present.

*If hepatitis D and E serology results are pending, but other criteria met, these can be reported and will be classified as "pending classification".

²Close contacts are defined as having cared for, lived with, spent significant time within close quarters (e.g. co-worker, daycare) or had direct contact with respiratory secretions and other body fluids (e.g., feces) in the 5 months prior to case onset.

APPENDIX B

This case report form will require information from both the clinical team and the parent/guardian of the case (or the case themselves if they are an adult).

Date reported to PHAC (dd/mm/yyyy):		Initial report Updated report	
Section 1: Reporter	details		
Public health autho	rity		
Name:		Title:	
Cell phone:		Email address:	
Province or Territory			
Clinician			
Name:		Title:	
Cell phone:		Email address:	
Organization:		Date of interview (dd/mm/yyyy):	

PART A: CLINICAL INFORMATION

Section 2: Case information				
First name:		Last name:		
Date of birth		Personal health		
(dd/mm/yyyy):		identifier:		
		Address during		
		the 5 months		
	Female □	prior to diagnosis		
Sex	Male □	Specify if there		
	Other □	was another		
		address during		
		the period		

Section 3: Current case st	atus		
Alive, recovered and discharged			
Alive, recovered and discharged			
Alive, discharged and reco	vering		
Alive, in hospital			
Alive, in intensive care (ICU	J/CCU)		
Deceased			
Unknown			
More information:			
Name of hospital where acute hepatit	e diagnosis of tis was made:	 Unknown □	
Mag liver transplant	Yes□	Name of hospital	Hospital
Was liver transplant required?	No □ Unknown □	and date of liver transplant if applicable:	Unknown Date
			Unknown □
Section 4: Presenting illne Please provide a summary prodromal symptoms) and	of the sympto		presenting illness (including
Symptom		om present	Symptom onset date (dd/mm/yyyy)
Jaundice	Yes□	No □	/ /
Nausea	Yes□	No □	/ /
Abdominal pain/ cramping	g Yes□	No □	/ /
Diarrhea	Yes□	No □	/ /
Bloody stool	Yes□	No □	/ /
Pale stool	Yes□	No □	/ /
Dark urine	Yes□	No □	/ /
Rash		No □	/ /
Vomiting Yes D		No □	/ /
Respiratory Symptoms –	Yes□	No □	/ /
shortness of breath, cough			
Upper Respiratory Sympto – runny nose, congestion, s throat		No □	/ /
Fever	Yes□	No □	/ /

Malaise/tiredness	Yes□ No □	/ /
Conjunctivitis	Yes□ No □	/ /
Other (please specify below):	Yes□ No □	/ /

Please provide clinical contact details of this presentation:						
Clinical contact	Clinical contacts during this presentation	Admission date – Discharge date (dd/mm/yyyy)				
Visited Family doctor or pediatrician	Yes□ No □					
Visited ER	Yes□ No □					
Admission to hospital (for at least 1 night)	Yes□ No □					
ICU/CCU admission	Yes□ No □					

Section 5: Laboratory results / Toxicology / Investigations

NOTE: please follow provincial guidelines/directives for laboratory testing. Please provide results of all tests performed.

					Date sample
			Not tested	Pending	collected (dd/mm/yyyy)
Laboratory marker					
Highest ALT					/ /
Highest AST					/ /
Highest Bilirubin					/ /
Highest INR					/ /
Highest Ferritin					/ /
				Date sample collected (dd/mm/yyyy)	
	Detected	Not detected	Not tested	Pending	
Infectious diseases					
CMV PCR in blood (indicate viral load if available)					/ /

Section 5: Laboratory results / Toxicology / Investigations

NOTE: please follow provincial guidelines/directives for laboratory testing. Please provide results of all tests performed.

results of all tests performed.			
EBV PCR in blood (indicate viral load if available)			/ /
Enterovirus PCR in blood (indicate viral load if available			/ /
HSV – 1 PCR in blood (indicate viral load if available)			/ /
HSV – 2 PCR in blood (indicate viral load if available)			/ /
HAV: PCR in blood if done, or stool (please specify)			/ /
HAV: IgG			/ /
HAV: IgM			/ /
HBV (HBsAg)			/ /
HBV DNA			/ /
HCV (Ab)			/ /
HCV RNA			/ /
HEV: IgM			/ /
HEV: IgG			/ /
HEV PCR in blood (or stool)- please specify			/ /
Adenovirus – stool sample			/ /
Adenovirus – respiratory sample			/ /
Adenovirus – blood sample (indicate viral load)			/ /
Adenovirus – other sample			/ /
Adenovirus genotyping (indicate sample used)			/ /
SARS-CoV-2 PCR – respiratory sample			/ /

Section 5: Laboratory results / Toxicology / Investigations NOTE: please follow provincial guidelines/directives for laboratory testing. Please provide results of all tests performed. SARS-CoV-2 anti-spike and/or anti-N antibody RSV PCR - respiratory sample Influenza PCR – respiratory sample Enterovirus PCR – respiratory sample Varicella PCR in blood Parvovirus B19 IgM or IgG or PCR, please indicate EBV serology (IgG and IgM) CMV serology (IgG and IgM) Stool PCR for norovirus and/or enterovirus (select those included if not all available) Other (please specify): Toxicology Heavy metal screen: Lead / Heavy metal screen: Arsenic Heavy metal screen: Mercury Drug screen: Peak acetaminophen concentration Urine toxicology (please provide / details of any positive tox results) **Investigations** Performed If yes, please summarise Date of test findings: Radiology:

Section 5: Laboratory results / Toxicology / Investigations NOTE: please follow provincial guidelines/directives for laboratory testing. Please provide					
results of all tests performed.					
Liver biopsy* (summarise histopathology report, including whether damage starting at portal tracts or diffuse)	Yes□ No □		/ /		
List immunohistochemistry stains performed* (adenovirus/CMV/EBV etc)	Yes□ No□		/ /		

Not be considered a recommended 7 mandatory test, based on elimeatheed.						
Section 6: Case medical and health history						
Did the case have COVID-19? Y	'es□ Suspecte	d□ Unknown	□ No □			
Was it confirmed by a test (most	Was it confirmed by a test (most recent episode)? Yes \square [PCR \square ; Rapid antigen test \square] No \square					
Date of onset (most recent episo	ode) (<i>dd/mm/yyy</i> y	<i>/)</i> :				
Please summarize any other pre	vious illnesses re	quiring treatmer	nt/care in the 5 r	nonths prior to		
diagnosis:						
Illness type (e.g.	Hospitalisation	Date of	Primary	Over the		
gastrointestinal illness, injury)	required	onset/ days	Symptoms	counter or		
	(yes/no)	to resolution		prescribed		
				medication		
				taken		
Please describe any other medication the case						
has been prescribed in the 5 months prior to						
diagnosis						

^{*}Not be considered a recommended / mandatory test, based on clinical need.

Does the case have any underlying medical	Yes□ No □
condition? Including liver	
related/metabolic/autoimmune/ischaemic	
If yes, details: (diagnosis, date of diagnosis,	/ /
medication)	
Is the case immunosuppressed?	Yes□ No □
If yes, details: (condition (include if primary,	
secondary, medication related), date of	
diagnosis, medication)	
Does or has the case take(n) any supplements or	Yes□ No □
medicines acquired, over the counter,	
purchased over the internet or accessed by any	
other methods? (Including herbal, alternative	
medicines, vitamins or other supplements);	
specifically, prompt acetaminophen/ anti-	
inflammatory drugs (e.g. aspirin,	
ibuprofen)/anticonvulsants in the 5 months prior	
to diagnosis?	
If yes, details: (product, dose and frequency,	
where purchased)	
Has the patient received any vaccine in the 5	Yes□ No □
months prior to diagnosis?	
If yes, details: (type, date of administration)	

Section 7: Interviewee details (case or parent/guardian)				
		Relationship to the		
Interviewee name:		case (if not		
		interviewing the case):		
Cell phone:		Email address:		

PART B: EXPOSURE INFORMATION

Section 8: Exposure to ill contacts					
Does the case regularly g	go to daycare or school? Yes □ No □				
Provide recent details of	illnesses or infections among close co	ontacts¹, including	group settings		
(e.g. outbreak in classroom	m), in the 5 months prior to diagnosis (of the case if know	n:		
Nature of contact	Illness type (e.g. Gastro, COVID-19)		Date of		
(household, daycare,			symptom		
etc.)			onset or test		
			result (if		
			asymptomatic)		
			/ /		
			/ /		
			/ /		
			/ /		
Have any close contacts	been jaundiced or had a similar	Yes□ No □			
condition (gastrointestina	l symptoms, etc.) in the 5 months				
prior to diagnosis of the c	ase?				
Section 9: Exposure to animals					
Has the case had contact with animals? Yes No IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII					

¹ Close contacts are defined as having cared for, lived with, spent significant time within close quarters (e.g. coworker, daycare) or had direct contact with respiratory secretions and other body fluids (e.g., feces) in the 5 months prior to case onset.

Section 10: Travel History	
In the 5 months prior to diagnosis of acute hepatitis, has the case had any day trips, travel and/or overnight visits to other households or locations? Please ensure to include any travel/trips to another province within Canada and outside Canada.	Yes No D If yes, specify province, territory (circle) or country: BC AB SK MB ON QC NB NS PE NL YK NT NU
Has any household contact travelled or has the case been in close contact with visitors in the 5 months prior to diagnosis? Please ensure to include any travel to or visitors from another province within Canada and outside Canada.	Yes No D If yes, specify province, territory (circle) or country: BC AB SK MB ON QC NB NS PE NL YK NT NU
Section 11: Any other information	
Are there any other remarkable	

Are there any other remarkable events, interactions, or experiences in the 5 months prior to diagnosis that have not been discussed so far that might be important or that you suspect may have caused or contributed to the illness? This may include parties or functions.

END OF QUESTIONNAIRE